Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone Says PD-L1 Meets Overall Survival Endpoint for NSCLC

publication date: Jan 19, 2022

Suzhou CStone Pharma announced a China Phase III trial of its PD-L1 (Cejemly®) met its overall survival endpoint as a first-line therapy for non-small cell lung cancer. The PD-L1, sugemalimab, was administered together with chemotherapy to patients with Stage IV NSCLC. In December, CStone was approved to launch the regimen in China for metastatic squamous and non-squamous NSCLC, based on progression-free survival data. In the US, EQRx owns rights to sugemalimab and plans to market it as a lower cost alternative to PD-1/PD-L1 drugs from big pharmas. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.